HUNTINGTON BEACH, Calif., Dec. 16, 2020 /PRNewswire-PRWeb/ — Primas Group today announces its new ScheduleNOW COVID-19 Vaccine Scheduling System, their web-based self-service scheduling tool that schedules BOTH of the required vaccination appointments within the mandatory time parameters. This “made-for-Covid-19-vaccination” software package provides on-site verification and ad-hoc scheduling management, complete with follow-up reminders via email, SMS, and phone calls. Appointments can be rescheduled easily or canceled by the patient through various multi-media channels without requiring the valuable time of the administration site staff.
ScheduleNOW can be implemented as a stand-alone package deployed in just one day upon completion of site configurations, OR in conjunction with external UC and contact center systems – including the Primas ground-breaking Primas CX Suite of Contact Center applications. Originally developed for one of the initial 150 COVID-19 vaccine deployment facilities in the USA, this flexible solution operates on premise or in the cloud. ScheduleNOW also supports multiple vaccination brands in multiple locations all with one system, as well as offering data integration to HL7 and PCI compliance.
To learn more, visit https://www.primas.net/schedulenow
ABOUT PRIMAS GROUP
Founded in 1994, Primas Group provides technology solutions designed for the contact center space serving customers worldwide. The Primas Group unique flagship product, Primas CX, is a comprehensive Omni Channel CX Suite of apps designed for existing premise-based contact center clients who want state of the art technology without undergoing massive upgrades or having to move to the cloud. The apps include virtually everything today’s contact centers want, and they are very cost-effective with implementations that take days instead of months. Primas also offers IVR and CTI programming, as well as other custom programming.
Media Contact
Nancy Gates, ngates@primas.net, +1 (954) 770-2805, ngates@primas.net
SOURCE Primas Group
Two immersive 2026 events in Seattle and Boston will offer up to 12 CE credits,…
Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth…
Study published by Centre for Neuro Skills researchers in Brain Injury journal argues current insurance…
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large,…
American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as…
TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard”…